Q&A column, 1/18

Create PDF

1. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71(9):3400–3409.
2. Kho DH, Zhang T, Balan V, et al. Autocrine motility factor modulates EGF-mediated invasion signaling. Cancer Res. 2014;74(8):2229–2237.
3. Kho DH, Nangia-Makker P, Balan V, et al. Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res. 2013;73(4):1411–1419.
4. Lincet H, Icard P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene. 2015;34(29):3751–3759.
5. Niinaka Y, Harada K, Fujimuro M, et al. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res. 2010;70(22):9483–9493.
6. Wang L, Hou G, Xue L, Li J, Wei P, Xu P. Autocrine motility factor receptor signaling pathway promotes cell invasion via activation of ROCK-2 in esophageal squamous cell cancer cells. Cancer Invest. 2010;28(10):993–1003.

Sixto M. Leal Jr., MD, PhD
Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill

Dr. Kiechle is consultant, clinical pathology, Cooper City, Fla. Use the reader service card to submit your inquiries, or address them to Sherrie Rice at srice@cap.org. Questions that are of general interest will be answered.